Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery↑Improving
- Strong Financial Health Score↑Improving
- Confirmed Technical Downtrend↑Improving
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $93.56, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for certain components, raw materials and services; Analyst target reached - limited upside remaining.
Medtronic plc is a global healthcare technology company that develops, manufactures, and sells medical devices across four segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — serving healthcare systems, physicians, and patients in more than 150 countries.... Read more
Hold if already holding. Not a fresh buy at $93.56, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for certain components, raw materials and services; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.5/10, moderate confidence.
Passes 8/11 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, news boost analyst cluster(3), earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: conservative.
About Medtronic plc.
About Medtronic plc.
Medtronic operates four reportable segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — selling implantable devices such as the Micra leadless pacemaker, Evolut TAVR valves, Inceptiv spinal cord stimulators, and the MiniMed 780G insulin pump system to healthcare systems, physicians, and patients in more than 150 countries. The company employs over 95,000 full-time staff, with 44% based in the U.S. or Puerto Rico, and in May 2025 announced plans to separate its Diabetes Operating Unit into an independent, publicly traded company within 18 months.
Medtronic earns revenue from device sales across its four segments, sold to hospitals, physicians' offices, and ambulatory care centers, with reimbursement from healthcare insurance providers a key factor in market access alongside product performance, price, and regulatory approval. The company manufactures the majority of its products in-house at facilities worldwide while procuring critical third-party services such as sterilization and, for reasons of quality assurance, cost, or availability, sources certain components, raw materials, and services from sole suppliers; several key products are manufactured or sterilized at a particular facility with limited options for alternate sterilization capacity. Growth also depends on investments and investment collaborations with medical-technology companies to access new technologies, a strategy that has produced acquisitions such as the Affera cardiac-mapping platform underlying its Sphere-9 catheter, alongside a hundreds-of-clinical-trials-per-year R&D program aimed at maintaining technological leadership across its device categories.
Show full overview
Medtronic's supply chain carries single-point failure risk that is unusual for a company of its scale: the 10-K discloses that, for reasons of quality assurance, cost-effectiveness, or availability, certain components, raw materials, and services are obtained from sole suppliers, and that several key products are manufactured or sterilized at a particular facility with constrained capacity and limited options for alternate sterilization sites. Because regulatory approval and licensing of a new manufacturing or sterilization facility takes time, the company states a third party may not be available on a timely basis to replace lost production capacity if such a facility were damaged or closed — a structural vulnerability distinct from the demand-side risks of competition or reimbursement pressure that dominate most of its other disclosed risk factors.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-09-04Recent Developments — Medtronic plc.
Latest news
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - simplywall.st — simplywall.st negative
- NEWS MDT Adds Rem700 Short Action Left Hand to CRBN Rifle Stock Lineup - Outdoor Wire — Outdoor Wire neutral
- NEWS Medtronic PLC $MDT Stock Position Decreased by California State Teachers Retirement System - MarketBeat — MarketBeat negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - Sahm — Sahm negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - sahmcapital.c — sahmcapital.com negative
Generated 2026-09-04T15:07:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers for certain components, raw materials and services10-K Item 1A: 'certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $93.56, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for certain components, raw materials and services; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $107.48 (+14.9%), stop $88.98 (−5.1%), A.R:R -0.1:1. Score 6.5/10, moderate confidence.
Take-profit target: $107.48 (-0.9% upside). Target $107.48 (+14.9%), stop $88.98 (−5.1%), A.R:R -0.1:1. Stop-loss: $88.98.
Concentration risk — Supplier: sole suppliers for certain components, raw materials and services; Analyst target reached - limited upside remaining.
Medtronic plc. trades at a P/E of 24.7 (forward 14.5). TrendMatrix value score: 5.7/10. Verdict: Hold.
34 analysts cover MDT with a consensus score of 4.0/5. Average price target: $103.
What does Medtronic plc. do?Medtronic plc is a global healthcare technology company that develops, manufactures, and sells medical devices across...
Medtronic plc is a global healthcare technology company that develops, manufactures, and sells medical devices across four segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — serving healthcare systems, physicians, and patients in more than 150 countries. Headquartered in Galway, Ireland, the company employs over 95,000 full-time employees, and in May 2025 announced plans to separate its Diabetes business into an independent, publicly traded company.